Icahn School of Medicine at Mount Sinai, New York, NY. RATIONALE: Long-term dietary implications of egg OIT (eOIT), including desensitization and sustained unresponsiveness (SU), are not well described. METHODS: Previously described egg allergic subjects (5-11 yo) were randomized to eOIT (n540, treated with eOIT up to 4 years) or placebo (n515, 1 year). Subjects passing a 10g OFC on therapy were considered desensitized and underwent a 10g OFC and open feeding 4-6 weeks after discontinuing therapy to determine SU. Long-term follow-up questionnaires (LFQ) assessing egg consumption and symptoms were administered annually for 5 years following trial completion. RESULTS: At study completion, 20/40 (50%) eOIT subjects were classified as SU, 11/40 (28%) subjects desensitized, and 9/40 (22%) not desensitized. Annual LFQ completion ranged from 76-82% of all subjects (85-95% of the SU group). At year 5, 93% (30/32) of eOIT subjects were ingesting some egg compared to 64% (7/11) of placebo (p50.029). 100% (19/19) of SU subjects were ingesting both concentrated and baked egg versus 43%, 17%, and 36% in the desensitized, not desensitized, and placebo groups, respectively. Decreased frequency and amount of egg ingestion and increased symptoms were observed in all non-SU groups versus the SU group. Epinephrine was required after concentrated egg ingestion in 3 non-SU subjects. CONCLUSIONS: Five years after study completion, eOIT treated subjects achieving SU were highly likely to consume and tolerate dietary egg, while other groups had more variable egg consumption and increased symptoms associated with consumption. Further study to develop biomarkers predictive of treatment response is necessary to mitigate risk and assess clinical outcomes with OIT. (JACI 2014;134:751-3). We undertook the BOPI study, a Phase 2b/3 randomized controlled trial to assess efficacy and safety of boiled peanut oral immunotherapy (OIT). METHODS: Children with peanut allergy confirmed at double-blind, placebo-controlled food challenge (DBPCFC) were randomised (2:1) to receive either oral immunotherapy (updosing using boiled peanut for ;6 months, followed by maintenance with roasted peanut) or standard treatment (allergen avoidance). Participants underwent repeat DBPCFC at 12 months to assess response, following which peanut OIT was stopped and sustained unresponsiveness assessed after 4 weeks (4-SU). Clinicaltrials.gov NCT02149719. RESULTS: Forty-seven children (8-17 years, 43% female) were randomised (32 to active treatment). Eight patients in the active group and 1 in the control group withdrew prior to primary outcome assessment, 4 due to treatment-related adverse events following initiation. Median cumulative eliciting dose prior to OITwas 143mg peanut protein (IQR: 43-443mg). 24/ 32 participants (100% per protocol) achieved the primary outcome of desensitisation to >1.4g peanut protein (P<.0001); of those 14 tolerated >4.4g peanut protein. 13/24 participants achieved 4-SU. There was no significant change in threshold in the control group (P>.05). There were 17 episodes of anaphylaxis occurring in 9 patients during home dosing. Boiled peanut OIT had a favourable safety profile, with under 2% of doses associated with gastrointestinal symptoms. CONCLUSIONS: Oral immunotherapy using boiled peanut is pragmatic and effective, with a favourable safety profile and level of sustained unresponsiveness after 1 year of treatment. We sought to identify key differentially expressed genes that may distinguish peanut allergic infants among those at high-risk for peanut allergy. METHODS: Eight infants aged 4-11 months with egg allergy and/or moderate-severe atopic dermatitis, but not yet eating peanut, were prospectively recruited from a tertiary care allergy clinic. Infants were classified as peanut allergic (PA), peanut sensitized but tolerant (PS-T) or peanut non-sensitized, non-allergic (NA) based on skin test, specific IgE and/or oral food challenge. RNA was isolated from whole blood and samples underwent RNA-seq library preparation and sequencing. Differential expression analysis was performed using DESeq2 R package and p-values were adjusted by FDR. RESULTS: Median age was 7.5 months and 50% were male. There was differential expression of 197, 198 and 557 unique genes in the PA, PS-T, and NA groups, respectively. Forty-one genes were up-regulated and 7 down-regulated in PA compared to NA (adj-p<0.05). The top 5 enriched genes in PA infants included: HLA-DRB6, CLC, SIGLEC8, SLC29A1 and ALOX15 (log 2 fold change >2.0, adj-p-value <0.01). Compared to PS-T, 4 genes were up-regulated and 6 down-regulated in PA (adj-p<0.05). There was a distinct subset of genes differentially expressed in PA compared to PS-T on hierarchical cluster analysis. Gene ontology enrichment revealed 138 pathways were differentially enriched between PA and PS-T. Four molecular function pathways (involving carbohydrate binding, neuropeptide binding and oxidoreductase activity) were enriched in PA compared to NA (adj-p<0.05). CONCLUSIONS: Differential gene expression is present among highrisk peanut allergic infants, which may provide insight on the pathogenesis of early infant peanut allergy. 
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